CN101129685A - 川芥软化散 - Google Patents
川芥软化散 Download PDFInfo
- Publication number
- CN101129685A CN101129685A CNA2007100708706A CN200710070870A CN101129685A CN 101129685 A CN101129685 A CN 101129685A CN A2007100708706 A CNA2007100708706 A CN A2007100708706A CN 200710070870 A CN200710070870 A CN 200710070870A CN 101129685 A CN101129685 A CN 101129685A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- grams
- powder
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 241000218176 Corydalis Species 0.000 claims description 18
- 241000628997 Flos Species 0.000 claims description 18
- 239000011812 mixed powder Substances 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 3
- 239000010419 fine particle Substances 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 241000411851 herbal medicine Species 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 9
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 208000002173 dizziness Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种具有治疗动脉硬化的中成药散剂技术领域,主要由以下配方配比组成:取川芎15克,荆芥10克,防风10克,细辛3克,香附子10克,薄荷10克,羌活10克,白芷10克,菊花15克,赤勺15克,元胡10克,龙胆草12克,本发明具有疏散风邪,活血散淤,通脑活络的作用,对治疗脑动脉硬化,偏正头痛或癫顶作痛、目眩都有显著疗效。
Description
技术领域
本发明涉及一种中成药散剂技术领域,尤其是治疗动脉硬化的散剂。
背景技术
动脉硬化是动脉的一种非炎症性病变,可使动脉管壁增厚、变硬,失去弹性和管腔狭小。动脉硬化有三种主要类型:细小动脉硬化,动脉中层硬化,动脉粥样硬化。细小动脉硬化是小动脉病变,主要发生在高血压病人;动脉中层硬化是中型动脉病变,常不产生明显症状,对人们危害性不大;动脉粥样硬化是动脉内壁有胆固醇等脂质的积聚。由于动脉粥样硬化对人类危害性较的,在此加以详细说明,本病多见于老年人,大多数在40岁以上。本病病因为多方面的,其中主要因素为脂质代谢紊乱、血液动力学改变,和动脉壁本身的变化。在高脂血症(主要血中胆固醇、甘油三酯及卜脂蛋白含量增加)患者中易发生本病。引起血脂增高可能是进食过多动物脂肪的食物如猪油、肥肉、肝、肾等内脏、蛋黄、奶油等。也可是患肝、肾疾病、糖尿病、甲状腺功能减退患者引起脂质代谢失常引起血脂增高。当动脉内压力增高,高压血流长期冲击动脉壁引起动脉内膜机械性损伤,造成血脂易在动脉壁沉积,因而高血压病患者易得动脉粥样硬化。嗜烟使血管长期痉挛,引起管壁营养不良也可使脂质在动脉壁上易于沉积。老年人动脉壁代谢夫调,可使脂质易于在动脉壁上沉积而发生动脉粥样硬化。
目前尚未有治疗动脉硬化的特效药,主要是通过药物治疗和手术治疗来控制病情的发展。药物治疗主要是用药物降血脂;手术治疗是对狭窄闭塞的动脉可施行血管再通或重建术,对冠状动脉粥样硬化,可行气囊导管经皮腔内冠脉成形术。但是此类药物控制病情容易让病患对药物产生依赖性,长期服用还会产生其他一些并发症,安全性能不高。
发明内容
本发明的目的是为其提供一种制作方便、无副作用、有效治疗动脉硬化的散剂制药。
一种治疗动脉硬化的散剂产品方案,所提供的技术方案是:取川芎15克,荆芥10克,防风10克,细辛3克,香附子10克,薄荷10克,羌活10克,白芷10克,菊花15克,赤勺15克,元胡10克,龙胆草12克,将细辛、香附子、白芷、赤勺、元胡等重要混合粉碎成粗粉颗粒;取川芎、荆芥、防风、羌活、菊花、龙胆草等重要混合粉碎成细粉;薄荷单独粉碎成极细粉;将细辛、香附子、白芷、赤勺、元胡等粉末混合物与川芎、荆芥、防风、羌活、菊花、龙胆草的细粉粉末混合搅拌均匀,混合粉末干燥后与薄荷搅拌均匀;过筛,保持颗粒能通过130~150目的筛;筛分后的颗粒散剂即可分剂量包装。以茶水作药引,冲服。
本发明的详细制备工序是:
1.配置好药材;
2.粉碎药材。将细辛、香附子、白芷、赤勺、元胡等重要混合粉碎成粗粉颗粒;取川芎、荆芥、防风、羌活、菊花、龙胆草等重要混合粉碎成细粉;薄荷单独粉碎成极细粉;
3.混合。将细辛、香附子、白芷、赤勺、元胡等粉末混合物与川芎、荆芥、防风、羌活、菊花、龙胆草的细粉粉末混合搅拌均匀,混合粉末干燥后与薄荷搅拌均匀;
4.过筛。用震动筛筛分细粉,保持细粉颗粒在130~150目大小;
5.包装。筛分后的细粉经质检后以每袋6克的剂量包装。
本发明中,所采用的药物如川芎具有活血理气、祛风止痛、降压、增加血液流量、抗血栓形成、抗肿瘤、增强机体免疫功能等作用;荆芥有发汗解表作用,且有祛风功效。主要治疗感冒风寒,发热恶寒、无汗、头痛、身痛等症;防风解表祛风、解痉止痛、有退热、镇静、抗菌的作用;细辛祛风,散寒,行水,开窍,治风冷头痛,鼻渊,齿痛,痰饮咳逆,风湿痹痛;香附子理气疏肝、健胃消食、有解热镇痛、保护心血管、利胆、抗菌的作用;薄荷清热疏风、利咽透疹、有退热、解毒、利咽的作用;羌活散表寒,祛风湿,利关节,治感冒风寒,头痛无汗,风寒湿痹,项强筋急,骨节酸疼,风水浮肿,痈疽疮毒;白芷祛风,燥湿,消肿,止痛,治头痛,眉棱骨痛,齿痛,鼻渊,寒湿腹痛,肠风痔漏,赤白带下,痈疽疮疡,皮肤燥痒,疥癣;菊花疏风清热、解毒平肝、有延缓衰老、保护心血管、抗血栓、抗菌、抗病毒的作用;赤勺有散淤、活血、止痛、泻肝火之效,主治月经不调、痰滞腹痛、关节肿痛、胸痛、肋痛等症;元胡有活血散瘀,利气止痛的功能;龙胆草有泻肝胆实火、清热健胃、除湿热等功能,主治高血压。
本发明与现有的治疗方法相比,对人体无任何伤害,长期服用不会造成对人体的副作用,而且只需坚持服用无须进行手术治疗或服用抗生素来改善控制病情。
具体实施方案
川芥软化散由以下配方配比组成:取川芎15克,荆芥10克,防风10克,细辛3克,香附子10克,薄荷10克,羌活10克,白芷10克,菊花15克,赤勺15克,元胡10克,龙胆草12克,将细辛、香附子、白芷、赤勺、元胡等重要混合粉碎成粗粉颗粒;取川芎、荆芥、防风、羌活、菊花、龙胆草等重要混合粉碎成细粉;薄荷单独粉碎成极细粉;将细辛、香附子、白芷、赤勺、元胡等粉末混合物与川芎、荆芥、防风、羌活、菊花、龙胆草的细粉粉末混合搅拌均匀,混合粉末干燥后与薄荷搅拌均匀;过筛,保持颗粒能通过130~150目的筛;筛分后的颗粒散剂即可分剂量包装。以茶水作药引,冲服,在具体实施过程中,可加黄芪,黄芪中黄芪苷对动脉硬化有很的控制作用。
下面结合具体操作方案进行说明:
实施例一
川芥软化散配伍:川芎15克,荆芥10克,防风10克,细辛3克,香附子10克,薄荷10克,羌活10克,白芷10克,菊花15克,赤勺15克,元胡10克,龙胆草12克。
制备方法:
1、配置好药材;
2、粉碎药材。将细辛、香附子、白芷、赤勺、元胡等重要混合粉碎成粗粉颗粒;取川芎、荆芥、防风、羌活、菊花、龙胆草等重要混合粉碎成细粉;薄荷单独粉碎成极细粉;
3、混合。将细辛、香附子、白芷、赤勺、元胡等粉末混合物与川芎、荆芥、防风、羌活、菊花、龙胆草的细粉粉末混合搅拌均匀,混合粉末干燥后与薄荷搅拌均匀;
4、过筛。用震动筛筛分细粉,保持细粉颗粒在130~150目大小;
5、包装。筛分后的细粉经质检后以每袋6克的剂量包装。
实施例二
川芥软化散配伍:川芎15克,荆芥10克,防风10克,细辛3克,香附子10克,薄荷10克,羌活10克,白芷10克,菊花15克,赤勺15克,元胡10克,龙胆草12克,黄芪7克。
制备方法同实施例一。
Claims (2)
1.一种具有治疗动脉硬化的中成药散剂,其特征在于川芎15克,荆芥10克,防风10克,细辛3克,香附子10克,薄荷10克,羌活10克,白芷10克,菊花15克,赤勺15克,元胡10克,龙胆草12克,将细辛、香附子、白芷、赤勺、元胡等重要混合粉碎成粗粉颗粒;取川芎、荆芥、防风、羌活、菊花、龙胆草等重要混合粉碎成细粉;薄荷单独粉碎成极细粉;将细辛、香附子、白芷、赤勺、元胡等粉末混合物与川芎、荆芥、防风、羌活、菊花、龙胆草的细粉粉末混合搅拌均匀,混合粉末干燥后与薄荷搅拌均匀;过筛,保持颗粒能通过130~150目的筛;筛分后的颗粒散剂即可分剂量包装。
2.根据权利要求1所述,其特征在于制作步骤是:
●配置好药材;
●粉碎药材,将细辛、香附子、白芷、赤勺、元胡等重要混合粉碎成粗粉颗粒;取川芎、荆芥、防风、羌活、菊花、龙胆草等重要混合粉碎成细粉;薄荷单独粉碎成极细粉;
●混合,将细辛、香附子、白芷、赤勺、元胡等粉末混合物与川芎、荆芥、防风、羌活、菊花、龙胆草的细粉粉末混合搅拌均匀,混合粉末干燥后与薄荷搅拌均匀;
●过筛,用震动筛筛分细粉,保持细粉颗粒在130~150目大小;
●包装,筛分后的细粉经质检后以每袋6克的剂量包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007100708706A CN101129685A (zh) | 2007-08-21 | 2007-08-21 | 川芥软化散 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007100708706A CN101129685A (zh) | 2007-08-21 | 2007-08-21 | 川芥软化散 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101129685A true CN101129685A (zh) | 2008-02-27 |
Family
ID=39127197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007100708706A Pending CN101129685A (zh) | 2007-08-21 | 2007-08-21 | 川芥软化散 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101129685A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2684567A4 (en) * | 2011-03-11 | 2014-09-24 | Miranda José Arturo Castañeda | HERBAL POLYMEDICAMENT FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS |
CN105833050A (zh) * | 2016-04-26 | 2016-08-10 | 于龙 | 一种治疗血管性头痛的中药汤剂 |
-
2007
- 2007-08-21 CN CNA2007100708706A patent/CN101129685A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2684567A4 (en) * | 2011-03-11 | 2014-09-24 | Miranda José Arturo Castañeda | HERBAL POLYMEDICAMENT FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS |
CN105833050A (zh) * | 2016-04-26 | 2016-08-10 | 于龙 | 一种治疗血管性头痛的中药汤剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104001131B (zh) | 一种防治应激性溃疡的内服中药 | |
CN103623339B (zh) | 一种外用治疗乳腺增生的药物及其制备方法 | |
CN101129685A (zh) | 川芥软化散 | |
CN105687961A (zh) | 一种治疗冠状动脉粥样硬化冲剂的制备方法 | |
CN1772148A (zh) | 接骨滋补胶囊及其制备工艺 | |
CN104189824A (zh) | 治疗老年咳喘的中药制剂 | |
CN104338052A (zh) | 治疗脑血栓的中药配方 | |
CN102526685A (zh) | 一种治疗颈椎病的药物 | |
CN105902766A (zh) | 治疗消化性溃疡的药物及制备方法 | |
CN105311374A (zh) | 一种用于治疗痛风性关节炎的药物 | |
CN104399013A (zh) | 一种治疗风寒外袭型三叉神经痛的中药组合物 | |
CN104998167A (zh) | 一种治疗牙龈痛肿的中药 | |
CN104161846A (zh) | 治疗肾盂肾炎的中药制剂 | |
CN103933136A (zh) | 一种治疗痔疮疾病的中药制剂及其制备方法 | |
CN105477458A (zh) | 一种治疗高血压的药物 | |
CN104027592A (zh) | 一种治疗瘀血型头痛病的中药 | |
CN102258672B (zh) | 一种治疗哮喘的中药 | |
CN104056217A (zh) | 治疗老年咳喘的中药制剂 | |
CN103393820A (zh) | 治疗疝气的中药组合物及其制备方法 | |
CN100500205C (zh) | 一种益寿养颜的膏药 | |
CN102370938A (zh) | 一种治疗心肌炎的中药 | |
CN108853405A (zh) | 一种治疗心血管疾病的盾叶新苷片及其炮制方法 | |
CN101057924A (zh) | 一种治疗腹胀的敷脐药物及其制备方法 | |
CN107569647A (zh) | 一种治疗胆结石的组合物及其制备方法 | |
CN105663448A (zh) | 一种治疗腰腿痛的外用膏药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080227 |